Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions.

[2][6] Phase IIb/III dose finding and evaluation trials for fragile X-syndrome were discontinued by the end of 2014.

[9][10] In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now.

[12] Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results.

[1] Recently, Stalicla, a biotech company applying artificial intelligence to identify subgroups of high-responder patients, acquired worldwide rights from Novartis to progress the drug for substance-use and neurodevelopmental disorders.